Single-dose secnidazole demonstrated comparable efficacy to 7-day BID metronidazole regimen2
Secnidazole vs. Metronidazole for the Treatment of BV
(clinical cure at day 28[%])*†
* A multicenter, double-blind, double-dummy randomized phase-III study comparing secnidazole and metronidazole.2
Clinical cure was defined as the normalization of the three Amsel criteria. 95% CI secnidazole-metronidazole [-0.098 ; 0.052].2
  • As many as 50% of patients DO NOT complete their full mulit-day course of metronidazole treatment3
  • A single-dose regimen supports adherence, helping the patient benefit from the efficacy of a full course of treatment.4
68% of patients treated with SOLOSEC did not require any additional treatment for BV5
SOLOSEC demonstrated clinically and statistically significant efficacy in the treatment of BV.5,6
SOLOSEC delivers potent antimicrobial dosing in a single 2g oral dose1
  • A single 2 g oral dose achieves average maximum plasma concentration (Cmax) 4 hours after dosing for fast systemic absorption.1
  • Plasma concentrations of secnidazole remain over the minimum inhibitory concentration (MIC) of BV- associated pathogens for longer than 72 hours.7

Mean Plasma Concentrations over Time (SOLOSEC vs. Metronidazole)7
* Assumes complete adherence to 500 mg BID metronidazole regimen. This is a pictorial representation of 2 products' pharmacokinetic profiles. There is no peer-reviewed study directly comparing the pharmacokinetics of SOLOSEC and metronidazole.
Help ensure patients' adherence in treating either BV or trichomoniasis with a complete single dose regimen1
Comparative Half-Lives of 5-Nitroimidazole Compounds7,8
Long half-life supports a 1-day, single dose regimen of SOLOSEC.7
SOLOSEC is the only antibiotic therapy that delivers a complete course of treatment for BV in just one oral dose1
solosec and current treatments for bacterial vaginosis comparison chart
side scroll icon
current treatments for bacterial vaginosis comparison chart
current treatments for bacterial vaginosis comparison chart
* Combination oral contraceptive ethinyl estradiol plus norethindrone
The comparative efficacy of SOLOSEC with the listed treatments has not been adequately studied. This is not a complete list of attributes for each product that may be important to a clinical decision. For the most updated information, consult the PI for each product.
Are you sure she only has BV?
Co-existence of BV-related pathogens and trichomoniasis is common.14
In the Longitudinal Study of Vaginal Flora, women who presented for routine health visits and were diagnosed with BV were 1.5 – 2x more likely to develop trichomonal, gonococcal, and/or chlamydial infections.15
70% of women with trichomoniasis were PCR-positive for BV.14
BV provides a high-pH environment, allowing T. vaginalis to grow.15

Vaginal pH
Single dose 2 g SOLOSEC demonstrated high clinical efficacy in patients co-infected with trichomoniasis and BV16
SOLOSEC is the only single dose oral antibiotic that provides a complete course of therapy to treat both BV and trichomoniasis.1
SOLOSEC is the only single dose oral antibiotic that provides a complete course of therapy to treat both BV and trichomoniasis.1
References:
1. SOLOSEC [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2021. 2. Bohbot JM, Vicaut E, Fagnen D, Brauman M. Treatment of bacterial vaginosis: a multi-center, double-dummy, randomized phase III study comparing secnidazole and metronidazole. Infect Dis Obstet Gynecol 2010;2010:1-6. 3. Bartley JB, Ferris DG, Allmond LM, Dickman ED, Dias JK, Lambert J. Personal digital assistants used to document compliance of bacterial vaginosis treatment. Sex Transm Dis 2004;31(8):488-491.23. 4. Kardas P, Bishai WR. Compliance in anti-infective medicine. Adv Stud in Med. 2006:6(July);652-658. 5. Hillier SL, Nyirjesy P, Waldbaum AS, et al. Secnidazole treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol 2017;130(2):379-386. 6. Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis [published correction appears in Am J Obstet Gynecol 2018;219(1):110]. Am J Obstet Gynecol 2017;217(6):678.e1-678.e9. 7. Nyirjesy P, Schwebke JR. Secnidazole: Next-generation antimicrobial agent for bacterial vaginosis treatment. Future Microbiol 2018;13:507-524. 8. Gillis JC, Wiseman LR. Secnidazole. A Review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis. Drugs 1996;51(4):621-638. 9. Flagyl [prescribing information]. New York, NY: Pfizer; 2021. 10. Tinidazole Tablets [prescribing information]. Buffalo Grove, IL: G.D. PACK Pharmaceuticals, LLC; 2018. 11. Clindesse [prescribing information]. Allegan, MI: Pharmacia & Upjohn Company, LLC; 2014. 12. Metrogel [prescribing information]. Sellersville, PA. Teva Pharmaceuticals, USA; 2005. 13. Nuvessa [prescribing information. Irvine, CA: Allergan Pharmaceuticals International, Ltd.; 2018. 14. Sobel JD, Subramanian C, Foxman B, Fairfax M, Gygax S. Mixed Vaginitis—More than Coinfection and with Therapeutic Implications. Curr Infect Dis Rep 2013;15:104-108. 15. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. J Clin Invest. 2011;121(12):4610-4617. 16. Muzny CA, Schwebke JR, Nyirjesy P, et al. Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study. Clin Infect Dis 2021.